Cardiovascular effects of sulphonylurea derivatives: Implications for the treatment of NIDDM?

Diabetologia: Clinical and Experimental Diabetes and Metabolism

Volumn 38, Issue 1, 1995, Pages 116-121

  Smits, P ^a   Thien, T ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

adverse effects; cardiovascular system; ischaemia; potassium channels; Sulphonylurea derivatives

Indexed keywords

POTASSIUM CHANNEL; SULFONYLUREA DERIVATIVE;

CARDIOVASCULAR SYSTEM; HEART MUSCLE ISCHEMIA; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

ANIMAL; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, NON-INSULIN-DEPENDENT; HEART; HUMAN; MYOCARDIAL ISCHEMIA; PANCREAS; POTASSIUM CHANNELS; SULFONYLUREA COMPOUNDS;

EID: 0028906582     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/BF02369361     Document Type: Article

References (58)

1. Epidemiology of some peripheral arterial findings in diabetic men and women: experiences from the Framingham study
2. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study
3. Diabetic retinopathy and cardiovascular disease in type II diabetics. The Framingham heart study and the Framingham eye study
4. Sulfonylureas in NIDDM
5. Oral hypoglycemic agents
6. ATP-regulated K-channels in cardiac muscle
7. Hyperpolarizing vasodilators activate ATP-sensitive K+-channels in arterial smooth muscle
8. Potassium channel openers and vascular smooth muscle relaxation
9. Cardiac ion channels
10. ATP-sensitive potassium channel modulation of the guinea pig ventricular action potential and contraction
11. Hyperpolarization and relaxation of resistance arteries in response to adenosine diphosphate
12. Adenosine, the heart, and coronary circulation
13. Coupling of ATP-sensitive K-channels to A1-receptors by G proteins in rat ventricular myocytes
14. Ultrastructural localisation of substance P and choline acetyltransferase in endothelial cells of rat coronary artery and release of substance P and acetylcholine during hypoxia
15. Rapid release of endothelin and ATP from isolated aortic endothelial cells exposed to increased flow
16. Local mechanisms of blood flow control by perivascular nerves and endothelium
17. Endothelium-derived hyperpolarizing factor (EDHF)
18. Membrane hyperpolarization is a mechanism of endothelium-dependent cerebral vasodilation
19. Vascular pharmacology of ATP-sensitive K-channels: interactions between glyburide and K-channel-openers
20. Comparison of KRN2391 with nicorandil and nifedipine on canine coronary blood flow: antagonism by glibenclamide
21. ATP-channels in coronary vasodilation during exercise
22. Blockade of the ATP-sensitive potassium channel modulates reactive hyperemia in the canine coronary circulation
23. Glibenclamide attenuates adenosine-induced bradycardia and coronary vasodilation
24. Vasodepressor mechanisms of 2-(1-octynyl)-adenosine (YT-146), a selective adenosine A2-receptor agonist, involve the opening of glibenclamide-sensitive potassium channels
25. Antiarrhythmic actions of the ATP-regulated K+-current activatied by pinacidil
26. Inhibition by glibenclamide of negative chronotropic and inotropic responses to pinacidil, acetylcholine, and adenosine in the isolated dog heart
27. ATP-regulated K+-channels protect the myocardium against ischemia/reperfusion damage
28. Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning
29. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs
30. Blockade of ATP-sensitive potassium channels increases infarct size but does not prevent preconditioning in rabbit hearts
31. Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels
32. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium
33. Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction
34. Myocardial protective effects of adenosine. Infarct size reduction with pretreatment and continued receptor stimulation during ischemia
35. Prevention of catecholamine-induced cardiac damage and death with a nucleoside transport inhibitor
36. Caffeine and theophylline attenuate adenosine-induced vasodilation in humans
37. Evidence for an antiaggregatory effect of adenosine at physiological concentrations and for its role in the action of dipyridamole
38. Adenosine attenuates the response to sympathetic stimuli in man
39. Adenosine attenuates the vasoconstrictor response to the cold pressor test in humans
40. Diagnostic and therapeutic use of adenosine in patients with supraventricular tachyarrhythmias
41. 1-receptors
42. The effects of the ATP-dependent potassium channel antagonist glyburide on coronary blood flow and susceptibility to ventricular fibrillation in anaesthetized dogs
43. Modulation of potassium channels by antiarrhythmic and antihypertensive drugs
44. ATP-sensitive potassium channel blocking agent ameliorates, but the opening agent aggravates, ischemia/reperfusion-induced injury
45. Slow elimination of glyburide in NIDDM subjects
46. Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use
47. What is the benefit of increasing the sulfonylurea dose?
48. The ATP-sensitive potassium channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog
49. Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis
50. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes mellitus: II. Mortality results
51. The prognostic importance of plasma glucose levels and of the use of oral hypoglycemic drugs after myocardial infarction in men
52. Coronary care for myocardial infarction in diabetics
53. Factors influencing the progress of atherosclerosis in the diabetic
54. Preventive tolbutamide treatment and arterial disease in mild hyperglycaemia
55. Vascular complications and long-term administration of oral hypoglycemic agents in patients with diabetes mellitus
56. Effects of glucose tolerance and treatment of abnormal tolerance on mortality in Malmöhus County, Sweden
57. Cardiovascular complications in diabetics and subjects with reduced glucose tolerance
58. Report of the committee for the assessment of biometric aspects of controlled trials of hypoglycemic agents